Close
Nordic 9Nordic 9

Golgi NueroSciences (investor - Corporate Investor)

Italy golgineurosciences.com
See something wrong or missing? Let us know
Offices:Milano
Average round investment:N/A USD
Average number per year:0.0
Distribution: 2024 (1)
Portfolio companies: Denmark Breye Therapeutics
Mostly invests in: Denmark Denmark (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Golgi NueroSciences

Name Criteria
Sweden Triathlon Group
77%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Active last 12 months: Yes
Sweden Ekeblad Bostad
77%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Active last 12 months: Yes
Finland DevCo Partners
73%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
Sweden Mertiva
73%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
United Kingdom The Oxford Foundry
73%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
Germany JIH family office
73%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
Denmark Steen Riisgaard
70%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Active last 12 months: Yes
Denmark Bagger-Sørensen Equity A/S
69%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Active last 12 months: Yes
Sweden Unionen
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Active last 12 months: Yes
Switzerland SNGLR Capital
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Top